Join
Live feed
·
PRReleasevia Quantisnow
Liminatus Pharma Inc. logo

Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy

ByQuantisnow·Wall Street's wire, on your screen.
LIMN· Liminatus Pharma Inc.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LIMN (Liminatus Pharma Inc.) and more on Quantisnow.